Narana Cables And Chemicals Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 19-12-2024
- Paid Up Capital ₹ 1.40 M
as on 19-12-2024
- Company Age 35 Year, 3 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 Cr
as on 19-12-2024
- Revenue -24.59%
(FY 2022)
- Profit -19.22%
(FY 2022)
- Ebitda 41.81%
(FY 2022)
- Net Worth 0.09%
(FY 2022)
- Total Assets 0.13%
(FY 2022)
About Narana Cables And Chemicals Pharmaceuticals
The Company is engaged in the Real Estate And Construction Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.40 M.
The company currently has active open charges totaling ₹2.50 Cr.
Gauri Mehta and Aniruddha Mehta serve as directors at the Company.
- CIN/LLPIN
U24232MH1990PTC178357
- Company No.
178357
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jan 1990
- Date of AGM
17 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Narana Cables And Chemicals Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gauri Mehta  | Director | 08-Jan-1990 | Current |
| Aniruddha Mehta | Director | 08-Jan-1990 | Current |
Financial Performance of Narana Cables And Chemicals Pharmaceuticals.
Narana Cables And Chemicals Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 24.59% decrease. The company also saw a substantial fall in profitability, with a 19.22% decrease in profit. The company's net worth moved up by a moderate rise of 0.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Narana Cables And Chemicals Pharmaceuticals?
In 2022, Narana Cables And Chemicals Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Umiya Holding Private LimitedActive 24 years 6 monthsGauri Mehta and Aniruddha Mehta are mutual person
- Invention Paints Private LimitedActive 18 years 1 month
Gauri Mehta and Aniruddha Mehta are mutual person
- Umiya Services Private LimitedActive 18 years 1 month
Gauri Mehta and Aniruddha Mehta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Vysya Bank Ltd Creation Date: 27 Nov 2001 | ₹2.50 Cr | Open |
How Many Employees Work at Narana Cables And Chemicals Pharmaceuticals?
Unlock and access historical data on people associated with Narana Cables And Chemicals Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Narana Cables And Chemicals Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Narana Cables And Chemicals Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
